RECRUITING

Contingency Management to Promote Smoking Cessation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Many hospitals and outpatient clinics often refer people who smoke to quitlines and provide prescriptions for smoking cessation medications, but patients rarely fully engage in counseling or use their cessation medications. This is a single-arm, open-label pilot study to provide feasibility metrics for a text-based contingency management (CM) intervention to increase engagement in smoking cessation treatment. All participants (N=20) will be referred to a state quitline and will receive a prescription for medication plus 12 weeks of a text-based CM intervention to increase engagement in quitline calls and varenicline utilization. The engagement of participants in quitline counseling will be tracked for 6 weeks and medication utilization for 12 weeks post-enrollment. The investigators will use mixed-methods to collect implementation and acceptability data to inform changes to the text-based contingency management (CM) intervention.

Official Title

Using Contingency Management to Promote Adherence to Smoking Cessation Treatment

Quick Facts

Study Start:2024-09-20
Study Completion:2025-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06456242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Smoked in the past 30 days
  2. * Smoke at least 1 cigarette per day when they smoke
  3. * ≥ 18 years old
  4. * Kansas resident
  5. * Speak/read English
  6. * Access to a mobile phone
  7. * Mobile phone receives text messages
  8. * No varenicline contraindications (no acute renal impairment)
  9. * Insurance coverage for varenicline
  10. * Have no significant co-morbidity (i.e., life-threatening illness, communication barriers or altered mental status)
  11. * Cognitively able to participate
  12. * Physically able to participate
  13. * Not pregnant/breastfeeding
  1. * Medically ineligible for varenicline
  2. * Patient on smoking cessation medication within 2 weeks of admission date
  3. * Patient already talked to quitline in the past 2 weeks.
  4. * Patients participating in other quit smoking program or research study

Contacts and Locations

Study Contact

Erica Cruvinel
CONTACT
913-945-6966
ecruvinel@kumc.edu
Vinita Devarasetty, MPH
CONTACT
913-617-1018
v210d808@kumc.edu

Study Locations (Sites)

University of Kansas Medical Center
Kansas City, Kansas, 66103
United States

Collaborators and Investigators

Sponsor: University of Kansas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-20
Study Completion Date2025-09

Study Record Updates

Study Start Date2024-09-20
Study Completion Date2025-09

Terms related to this study

Additional Relevant MeSH Terms

  • Smoking Cessation